The 6 analysts offering 12-month price forecasts for NeuBase Therapeutics Inc have a median target of 15.50, with a high estimate of 18.00 and a low estimate of 13.00. The median estimate represents a +93.51% increase from the last price of 8.01.
The current consensus among 6 polled investment analysts is to Buy stock in NeuBase Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.23
Reporting Date Aug 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.